Send us Fan Mail

Yarin Gaon is the Managing Partner of Fractional Partners, a growth advisory firm built for post-product-market-fit companies that are not yet ready to scale cleanly. He is an entrepreneur-turned-investor who started building companies as a teenager, created and sold Israel’s largest e-commerce platform for military goods, and later worked with hundreds of founders through a venture capital firm.

This conversation is important because most companies making between $1 million and $20 million don’t go under due to market issues. Instead, they often fail because they become too complicated, the founder keeps saying yes to everything, and the leadership team confuses busywork with real progress. Maxim and Yarin discuss the planning gap: when founders should stop adding more products, channels, and projects and instead focus on making clear choices about the kind of company they want to build.

5 Key Topics Covered

• Yarin’s founder-to-investor journey — Yarin shares how he started his first company at 14, built and exited an e-commerce business, and later worked with hundreds of founders before launching Fractional Partners.
• Why good companies stall after early traction — The conversation explores why growth by addition works early, but becomes dangerous once a company has found product-market fit and needs focus.
• Strategy before execution — Yarin explains why founders often think they have an execution problem when the real issue is unclear strategy, unclear priorities, and too many competing directions.
• Capital allocation as the founder’s real job — Maxim and Yarin discuss why scaling requires founders to think less like operators and more like allocators of time, money, people, and attention.
• The danger of optimizing complexity — The episode breaks down why systems, frameworks, and operating rhythms can become traps if they are used to organize a business that is already too unfocused.

3 Key Insights

• Early-stage companies can grow by saying yes, but scaling companies grow by deciding what to stop doing. The discipline to subtract is often what separates momentum from stagnation.
• Many founders mistake confusion about strategy for a problem with execution. Adding more meetings, KPIs, or systems won't help if the business hasn't clearly decided on its customers, products, position, and priorities.
• The right investor or advisor offers more than just money. For companies stuck in that tricky middle ground between gaining initial traction and growing bigger, advice, spotting patterns, and strong decision-making can be more helpful than the investment itself.

Links

• Fractional Partners: https://www.fractional.partners/
• Yarin Gaon on LinkedIn: https://www.linkedin.com/in/yaringaon/
• Growth Decisions Canvas: https://www.fractional.partners/free-tools/growth-deicisions-canvas
• Future Ventures Corp: https://ca.linkedin.com/company/future-ventures-corp
• Subscribe to Scaling with Clarity: https://www.youtube.com/channel/UCZgPPHfPBZz-r5NQLq_dWfA/

This episode has been brought to you by the Capital Intelligence Platform: https://capital.futureventures.ca/

About the Guest

Yarin Gaon is the Managing Partner of Fractional Partners, where he helps post-product-market-fit companies close the gap between early traction and scalable growth. He is an entrepreneur-turned-investor who has built, scaled, and exited companies, including Israel’s largest e-commerce platform for military goods. Through Fractional Partners, he works with founders and leadership teams to create clarity, improve decision-making, and build companies that can scale without drowning in complexity.

Send us Fan Mail

Joerg Erlemeier is the cofounder and COO of QUCOXX, a platform powered by AI that helps small and medium businesses improve their operations, sales, and finances. With over 30 years of experience working in big organizations, during times of change, and in consulting, Joerg decided to start his own business. He believes that small and medium-sized enterprises form the backbone of the economy, but they often don’t have the same strategic guidance, tools, or support to execute their plans as big companies do.

This conversation is important because growth isn’t just about getting bigger; it’s often about making things clearer. Maxim and Joerg talk about why small companies find it hard to switch from just working hard to developing steady, repeatable processes. They also explain how AI can help with better decision-making and why future growth requires founders to put systems in place instead of working harder. The talk is simple and helpful, especially for those trying to grow without adding too much extra work.

5 Key Topics Covered

● Why QUCOXX was built for SMEs — Joerg explains why small and medium-sized businesses need faster, more affordable access to enterprise-grade operating expertise.

● The performance gap between SMEs and large corporations — The conversation explores why smaller companies often lag in operational efficiency, not because they lack ambition, but because they lack structure, capacity, and tools.

● Growth as an execution challenge — Joerg breaks down the common bottlenecks around sales, marketing, positioning, financial discipline, and internal operating models.

● What founders should borrow from large companies — The episode draws a sharp line between bad corporate bureaucracy and useful operating discipline, including decision rights, priorities, KPIs, and accountability.

● AI, data, and operational clarity — Joerg and Max discuss why AI is only useful when a company has clean information, clear priorities, and a disciplined process for turning insight into action.

3 Key Insights

1. SMEs do not need to become large corporations, but they do need to become more disciplined. The goal is not bureaucracy; the goal is clear priorities, ownership, measurement, and execution.
2. Founder-led growth eventually becomes a constraint if everything still depends on the founder. Scaling requires leaders to let go, delegate decisions, and build trust in the team’s ability to execute.
3. AI will not fix a messy business by itself. It can accelerate decisions and improve performance, but only when the company already has the right data, structure, and operating rhythm in place.

Links

● QUCOXX: https://www.qucoxx.com/
● Joerg Erlemier on LinkedIn: https://de.linkedin.com/in/joerg-erlemeier
● Future Ventures Corp: https://ca.linkedin.com/company/future-ventures-corp
● Subscribe to Scaling with Clarity: https://www.youtube.com/@Future.Ventures

This episode has been brought to you by the Capital Intelligence Platform: https://capital.futureventures.ca/

About the Guest

Joerg Erlemeier is the Cofounder and COO of QUCOXX, an AI-powered platform built to help small and medium-sized enterprises improve performance across operations, finance, and growth. He brings more than 30 years of experience across business transformation, large-company operating environments, and global execution. At QUCOXX, he is focused on making practical, high-quality operating expertise more accessible to the companies that form the backbone of the economy.

Send us Fan Mail

Esra Kaygin is the founder and CEO of Hirize, an AI company building infrastructure for how organizations process, understand, and structure document-based data. Before Hirize, Esra worked as a headhunter, built and exited an early AI scheduling tool, and spent seven years on the venture capital side investing across marketplaces, fintech, deep tech, semiconductors, lab-grown diamonds, and defense. She brings the rare founder-investor perspective: she has seen the startup game from both sides of the table, and she is now back in the arena building again.

This conversation is important because AI is only as good as the data it uses. People talk about agents, copilots, and automation for businesses, but most companies still deal with messy documents, broken processes, and unreliable tools for extracting data. Max and Esra explore the behind-the-scenes technology that makes AI work, like understanding documents, rating confidence levels, ensuring data accuracy, and recognizing that 80% accuracy isn’t enough when making real business decisions.

5 Key Topics Covered

● From headhunting to AI founder — Esra shares how repetitive recruiting workflows led her to build her first AI scheduling startup, exit it, and eventually return to entrepreneurship after seven years in venture capital.

● Why Hirize started with HR and expanded beyond it — The company began by solving HR workflow problems. Still, the bigger pain point became clear: existing document parsers were too inaccurate for modern AI workflows.

● Parsing vs. document intelligence — Esra explains why extracting text from a document is only the first step; the real value comes from understanding meaning, validating fields, flagging uncertainty, and connecting documents inside a workflow.

● Why enterprise AI breaks without clean data — LLMs can look impressive in demos, but once deployed inside large companies with messy documents, complex systems, and critical decisions, accuracy and hallucination become serious business risks.

● What comes next for Hirize — Esra outlines the company’s move toward one API for document intelligence, automatic document classification, a planned rebrand to Field, voice and video parsing betas, and the need to scale the team through a seed round.

3 Key Insights

1. AI does not eliminate the data problem — it exposes it. Companies that cannot structure, verify, and trust their own information will struggle to get real value from agents or automation.
2. Accuracy isn't just an extra feature in enterprise AI; it's the main goal. When a system handles invoices, health records, insurance policies, purchase orders, or candidate information, being "mostly right” can still lead to serious issues.
3. Founder speed matters, but so does judgment. Esra is direct about the cost of early wrong hires, the illusion that founders have more time than they do, and the importance of building a team that works like a machine.

Links

● Hirize: https://hirize.ai/

● Esra Kaygin on LinkedIn: https://www.linkedin.com/in/esranur-k-5b12768/

● Future Ventures Corp: https://ca.linkedin.com/company/future-ventures-corp

● Subscribe to Scaling with Clarity: https://www.youtube.com/@Future.Ventures

This episode has been brought to you by the Capital Intelligence Platform: https://capital.futureventures.ca/

About the Guest

Esra Kaygin is the founder and CEO of Hirize, an AI company that helps organizations analyze and organize data from complex documents. Before this, she started and sold an AI scheduling business and spent seven years investing in technology startups as a venture capital partner. Now, she is working on building Hirize into a platform that uses AI to improve workflows in HR, finance, healthcare, and more.

Send us Fan Mail

Alan McLaren is the co-founder of Strata Originals, where he helps CEOs, founders, and executive teams understand one of the most overlooked forces in leadership: how they are actually experienced by other people. His work sits at the intersection of leadership, storytelling, trust, brand, and high-stakes communication. In these rooms, investors, boards, teams, and buyers often make decisions before anyone says the quiet part out loud.

This conversation is important because most leaders think they're judged by their strategy, intelligence, or words. Alan explains that people can often tell who you are even before you speak. Max and Alan talk about how pressure can show hidden leadership problems, why trust can break in small moments, and how founders trying to raise money, lead teams, or sell their businesses should be aware of the signals they send when things get tense.

5 Key Topics Covered

• Leadership Signal — why the way a founder lands in the room can determine whether people align, hesitate, or quietly disengage.
• Pressure and distortion — how challenges to identity, credibility, or authority can trigger reactions leaders do not even realize they are broadcasting.
• Trust in capital and boardrooms — why investors, teams, and acquirers are constantly asking whether they feel safe and whether they trust the person leading.
• Founder bottlenecks and valuation risk — how a business that depends too heavily on one person becomes harder to scale, delegate, and sell.
• The evolution of the CEO role — why leaders move from doing everything, to delegating, to becoming the bandleader responsible for vision, culture, and trust.

3 Key Insights

1. Leadership is not just communication. A founder can say the right words and still lose the room if their tone, posture, defensiveness, or energy sends a different signal.
2. Trust breaks faster than most leaders realize. One dismissive comment, one defensive reaction, or one moment of command-and-control behaviour can shut people down long before the meeting ends.
3. Scale requires the founder to become less central to the machine. The stronger the team, the clearer the delegation, and the lower the key-person risk, the more valuable and durable the business becomes.

Links

● Strata Originals: https://ca.linkedin.com/company/strataoriginals

● Alan McLaren on LinkedIn: https://ca.linkedin.com/in/alanmclaren

● Future Ventures Corp: https://ca.linkedin.com/company/future-ventures-corp

About the Guest

Alan McLaren is the co-founder of Strata Originals, a company that helps leaders improve how they perform in stressful situations. He used to run a marketing agency for almost twenty years before switching to work on leadership, branding, and building trust. Now, Alan helps founders and CEOs spot hidden signals and misunderstandings that affect how they lead, get funding, build teams, and grow their businesses.

Send us Fan Mail

In a moment where everyone is racing to build with AI, Dennis Bruce is the voice telling founders to slow down enough to know where they're going. With more than three decades navigating large-scale technology transformations — from integrating minicomputers and mainframes at the UN in the 1980s, to rebuilding the privatized Entel (now Telecom Argentina) during Latin America's privatization wave, to turnarounds across airports, retail, and property management — Dennis has seen every flavor of ambitious tech project. In 2007, he founded Tangonet Solutions, which today collaborates with 200+ technology professionals across the Americas, pairing North American companies with deep Argentine engineering talent to close the gap between business strategy and technical execution.

This conversation matters because it punctures the hype without dismissing the technology. Dennis is bullish on AI — but he's blunt about what it can't do. You can generate 30,000 lines of code in seconds; you cannot vibe-code your way to an enterprise. Maxim and Dennis dig into why most projects still fail, what separates a weekend prototype from a production system, and why — after all the talk about models and tooling — the hardest part of any transformation is still people. If you're a founder deciding whether to build, buy, or go to market, this episode gives you a sharper lens.

5 Key Topics Covered

• The "Ferrari" problem — AI lets you move faster than ever, but speed only matters if you actually know your destination.
• Why projects really fail — most teams build before they understand the outcome, and discover product-market fit too late.
• Prototype vs. enterprise — the leap from a Replit or Cursor demo to a maintainable, secure, scalable system is where the real work lives.
• People are the weakest link — governance and process you can engineer, but change management and sponsorship decide whether anything ships.
• The tooling shift — why Claude Code has become the standard, how Whisperflow changes daily workflow, and the case for going all in on one stack.

3 Key Insights

1. AI has driven the cost of building toward zero, but not the cost of knowing what to build — so the durable advantage is no longer the code itself, but distribution, proprietary data, or genuine speed to market.
2. Raw output is a vanity metric; teams that skip software-engineering fundamentals end up funding teardowns and "rescue projects" that cost far more than doing it right the first time.
3. The smartest move with an internal tool often isn't taking it to market — it's using it to make your own business faster and more efficient, turning the build into a competitive edge rather than another product fighting for oxygen.

Links

• Tangonet Solutions: https://tangonetsolutions.com/
• Dennis Bruce on LinkedIn: https://www.linkedin.com/in/dennisbrucetechgrowth/es
• Future Ventures Corp: https://ca.linkedin.com/company/future-ventures-corp
• Subscribe to Scaling with Clarity: https://www.youtube.com/@Future.Ventures

About the Guest

Dennis Bruce is the General Director of Tangonet Solutions, with more than 30 years of experience in technology projects across the Americas. He has worked on projects like integrating UN systems, selling Argentina's telecom industry to private companies, and helping big companies update their technology. Today, he helps businesses find top Argentine engineers to turn their plans into real results.

Send us Fan Mail

Damian Roller is a Partner at Inovexus, a community-backed founders club that invests in and supports early-stage European startups across the DACH region — Germany, Austria, and Switzerland. Before backing founders, he was one: born in Poland, raised in Germany, he built and sold an e-commerce company at university, spent a couple of years day trading and in real estate, then joined the founding team of a Munich B2B SaaS company in 2016. Eight years, one pandemic, and one exit later, he came out the other side with a hard-won operator's view of what scaling actually takes. Today, he helps run a network of 2,500+ investors and roughly 500 mentors — people who have already done the thing the founder in front of them is trying to do.

This conversation is important because Damian is at the point where most founders get stuck: the difference between building a product and scaling a business. His main point is direct and timely — AI has made building cheaper, so now what sets you apart is distribution. This change changes how founders should think about raising money, choosing mentors, entering markets, and deciding whether to build or buy, which can quietly cause companies to fail. If you're a founder deciding whether to grow, seek funding, or just focus on shipping, this episode helps you see things more clearly.

Key topics covered

• The Inovexus model — How a founders club backed by experienced angels and operator-mentors invests deal-by-deal and stays on the journey long-term, not just for a cohort.
• AI and the disappearing moat — Why a three-person team can now do what once took fifteen, and why that makes go-to-market the real battleground.
• The real bottleneck — Damian's case that capital is rarely the constraint; closing a founder's knowledge gaps is.
• Why Europe taxes its founders — How fragmented languages, regulations, and sales cultures force European startups to win country by country, and what that means for the jump to the US.
• The B2B SaaS "apocalypse" and build-vs-buy — Whether AI wipes out software companies, and the total-cost-of-ownership math that founders underestimate.

Three key insights

1. When building gets cheap, distribution becomes the moat. The hard problem shifts from making the product to reaching customers across fragmented markets — which is precisely where a strong network and operator mentorship earn their keep.
2. Capital is rarely the bottleneck; standing still is. A skilled founder usually has a clear product vision but may overlook some things. The right mentor helps guide the process, turning a long search into a more direct path from start to finish.
3. Europe's fragmentation is a real cost, but a shrinking one. Winning market by market is a tax on European founders — yet cross-border thinking is becoming a core founder skill, and rushing to the US unprepared punishes more often than it rewards.

Links

• Inovexus: https://inovexus.com/
• Damian Roller on LinkedIn: https://de.linkedin.com/in/damianroller
• Future Ventures: https://ca.linkedin.com/company/future-ventures-corp
• Scaling with Clarity: https://www.linkedin.com/showcase/futureventures-podcast/

About the guest

Damian Roller is a Partner at Inovexus and co-founder of its German entity, expanding the firm's model across the DACH region. A four-time builder turned investor, he started and sold his first company at university before helping found and scale a Munich-based B2B SaaS company to a successful exit over eight years. He now spends his days finding strong founders and connecting them to a community of 2,500+ investors and roughly 500 operator-mentors.

This episode of Scaling with Clarity has been brought to you by the Capital Intelligence Platform — capital.futureventures.ca

Send us Fan Mail

Robert Stanley isn't a healthcare lifer. He spent most of his career in technology — running IT projects for big banks, telcos, and airlines — before moving into home care about a decade ago and building one of Ontario's established providers. That outsider's vantage point is exactly what makes this conversation worth your time. Where insiders see a system to optimize, Robert sees one that's structurally broken: wired to reward visits, procedures, and ambulance rides, with almost nothing that pays anyone to prevent the crisis in the first place. The math behind his urgency is hard to argue with — Canada's population of 82-year-olds peaks around 2051, and demand only climbs from here.

His idea is called Comprehensive Healthcare at Home: continuously monitor at-risk seniors and send a nurse or therapist when something seems wrong — often weeks before it would lead to an emergency room visit. But what makes CHA different isn't just the technology. It's how he set it up. Robert launched the care company first and treated it as a testing ground, so the technology became part of routines his clinicians already trusted, rather than being added on top. That's the key difference because most healthcare trials fail not because of the idea itself, but because they don’t fit into the busy schedule of overworked clinicians. For entrepreneurs facing a slow, regulated market, this is a lesson in earning the right to make changes.

Topics Covered

• The prevention problem — why a system that funds episodic care has no incentive to stop the crisis before it happens.
• Building care first, tech second — how running a home care company turned product-market fit into a non-question.
• Ambient monitoring in practice — optical sensors, smart mattresses, and predicting falls up to four weeks out.
• Data as the long-term moat — why the longitudinal dataset, not the hardware, becomes the company's most valuable asset.
• The national health record vision — the case for a federated, interoperable record and hospital-at-home at scale.

Key Insights

• Prevention is cheaper than almost anyone realizes, and the system ignores it anyway. A urinary tract infection caught early costs roughly $20 in antibiotics; missed, it can escalate to sepsis, a multi-week hospital stay near $20,000, and meaningful mortality risk — yet nothing in the funding model rewards catching it early.
• The hard part isn't the AI, it's the clinical plumbing. Alerts are useful only if they appear in the workflows clinicians already use. That's why CHA sends its signals through the same electronic record that their teams have trusted for years, instead of asking busy staff to learn something new.
• Owning the data eventually matters more than owning the device. Today, CHA is essentially an assistive tool with clinicians making every decision. Still, the continuous, anonymized picture of aging its building could become a defensible asset — even an early-warning system for the next pandemic.

Links

• Scaling with Clarity Podcast: https://www.linkedin.com/showcase/futureventures-podcast/
• CHA Group / CHAH AI Care: https://chah.ai/
• Robert Stanley on LinkedIn: https://www.linkedin.com/in/rjastanley/
• Future Ventures Corp: https://www.linkedin.com/company/future-ventures-corp
• Watch on YouTube: https://youtu.be/OInk-HpvUOc

About Robert Stanley

Robert Stanley is the Founder and CEO of CHA Group, the parent company of State Home Nursing Care Services and CHA Technology. After a long career in technology delivering large-scale IT projects, he moved into home care a decade ago. He built one of Ontario's established providers before turning his focus to predictive, technology-enabled care. Today, he's pioneering Comprehensive Healthcare at Home, a model that combines AI-powered monitoring with clinical response to keep vulnerable seniors safe, independent, and out of the hospital.

This podcast has been brought to you by the Capital Intelligence Platform: capital.futureventures.ca

Send us Fan Mail

Greg Miles is the founder and CEO of Milestone Gyno-Mics, a biotech company developing the first AI-powered, non-invasive blood test for endometriosis. He is one of the first bioinformatics PhDs in the U.S., with over 15 years of experience in genomics, diagnostics, and AI. He left a 10-year job at Agilent to focus on this project. His motivation is personal: he lost both grandparents to leukemia that was diagnosed too late, and he watched a loved one struggle for 12 years seeing many doctors before finally being diagnosed with endometriosis by a surgeon.

This conversation matters because endometriosis affects more than 1 in 10 women, is the leading cause of infertility, and is invisible on imaging more than 95% of the time — leaving most women on a decade-long diagnostic odyssey. Greg's thesis is blunt: endometriosis behaves like cancer (a recent paper found it shares all eight hallmarks), so we should detect it like cancer. The result is a clear-eyed look at why women's health has been underfunded and overlooked, how AI changes the math on early detection, and why the next major breakthrough in medicine may be diagnosis, not treatment.

Key Topics Covered

1. The diagnostic gap in women's health — Why early detection exists for breast cancer but almost nowhere else, and what that absence costs women in lost years and lost fertility.
2. Endometriosis as a cancer-like disease — How endo shares all eight hallmarks of cancer, and why that reframing should change how we diagnose and treat it.
3. How the AI blood test works — Reading three distinct biological signals from a simple arm draw and using machine learning to turn 20,000+ data points into a single diagnostic signature.
4. The economics of delayed diagnosis — The roughly $200K-per-patient cost of a 10-year delay, and why insurers, fertility clinics, and employers all have skin in the game.
5. What investors should actually scrutinize — The four things that separate a real diagnostic from a hyped one, from sensitivity and specificity to the integrity of the held-out data.

Key Insights

• Early detection is the key to everything downstream. Catch endometriosis in the first couple of years, and hormone therapy and surgery are far more likely to work; wait, and the disease spreads, recurs, and can close the window to start a family.
• The "yellow light" problem is the tell. Plenty of companies tout 90% accuracy while quietly parking 30–50% of patients in an inconclusive bucket — and no insurer pays for a test that can't commit to an answer.
• Repurposed drugs may be the fast track to treatment. Because endometriosis is a systemic, inflammatory disease recently linked to some 600 comorbidities, existing drugs with cleared safety profiles — GLP-1s among them — could leap straight toward endometriosis trials.

Links

• Milestone Gyno-Mics: https://www.milestonegx.com/
• Connect with Greg Miles: https://www.linkedin.com/in/gregory-miles
• Scaling with Clarity: https://www.linkedin.com/showcase/futureventures-podcast/

About the Guest

Greg Miles is the founder and CEO of Milestone Gyno-Mics, a biotechnology company developing a non-invasive, AI-powered blood diagnostic platform for women's health. One of the first bioinformatics PhDs trained in the United States, he brings more than 15 years of experience across genomics, diagnostics, and artificial intelligence, including a decade at Agilent. His mission is to collapse the years-long diagnostic delay women face for conditions like endometriosis — starting with a single blood test.